Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 199

1.

Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.

Woods B, Veenstra D, Hawkins N.

Value Health. 2011 Dec;14(8):989-1001. doi: 10.1016/j.jval.2011.05.048. Epub 2011 Nov 12.

PMID:
22152167
[PubMed - indexed for MEDLINE]
2.
3.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

PMID:
17610808
[PubMed - indexed for MEDLINE]
Free Article
4.

The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.

Fleeman N, Martin Saborido C, Payne K, Boland A, Dickson R, Dundar Y, Fernández Santander A, Howell S, Newman W, Oyee J, Walley T.

Health Technol Assess. 2011 Sep;15(33):1-102. doi: 10.3310/hta15330. Review.

PMID:
21906462
[PubMed - indexed for MEDLINE]
Free Article
5.

Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.

Dranitsaris G, Verma S, Trudeau M.

Am J Clin Oncol. 2003 Jun;26(3):289-96.

PMID:
12796603
[PubMed - indexed for MEDLINE]
6.
7.

Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil.

Fonseca M, Araújo GT, Saad ED.

Rev Assoc Med Bras. 2009 Jul-Aug;55(4):410-5.

PMID:
19750307
[PubMed - indexed for MEDLINE]
Free Article
8.
9.

Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.

Moeremans K, Annemans L.

Int J Gynecol Cancer. 2006;16 Suppl 2:576-8.

PMID:
17010076
[PubMed - indexed for MEDLINE]
10.

Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.

Lux MP, Wöckel A, Benedict A, Buchholz S, Kreif N, Harbeck N, Kreienberg R, Kaufmann M, Beckmann MW, Jonat W, Hadji P, Distler W, Raab G, Tesch H, Weyers G, Possinger K, Schneeweiss A.

Onkologie. 2010;33(4):155-66. doi: 10.1159/000286233. Epub 2010 Mar 19.

PMID:
20389141
[PubMed - indexed for MEDLINE]
11.

Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.

Karnon J, Delea T, Barghout V.

Eur J Health Econ. 2008 May;9(2):171-83. Epub 2007 Jun 30.

PMID:
17602251
[PubMed - indexed for MEDLINE]
12.

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M; ATAC trialists.

J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6. Erratum in: J Natl Cancer Inst. 2012 Nov 21;104(22):1772.

PMID:
22395643
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.

Gil JM, Rubio-Terrés C, Del Castillo A, González P, Canorea F.

Clin Transl Oncol. 2006 May;8(5):339-48.

PMID:
16760009
[PubMed - indexed for MEDLINE]
14.

[Cost-benefit analysis of anastrazol and tamoxifen in adjuvant treatment of hormone receptor-positive, post-menopausal breast cancer].

Gamboa O, Díaz S, Chicaíza L, García M.

Biomedica. 2010 Jan-Mar;30(1):46-55. Spanish.

PMID:
20890549
[PubMed - indexed for MEDLINE]
Free Article
15.

Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.

Imai H, Kuroi K, Ohsumi S, Ono M, Shimozuma K.

Breast Cancer. 2007;14(1):81-7. Review.

PMID:
17245000
[PubMed - indexed for MEDLINE]
Free Article
16.
18.

Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.

Simons WR, Jones D, Buzdar A.

Clin Ther. 2003 Nov;25(11):2972-87.

PMID:
14693319
[PubMed - indexed for MEDLINE]
19.

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Punglia RS, Burstein HJ, Winer EP, Weeks JC.

J Natl Cancer Inst. 2008 May 7;100(9):642-8. doi: 10.1093/jnci/djn100. Epub 2008 Apr 29.

PMID:
18445827
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.

Rocchi A, Verma S.

Support Care Cancer. 2006 Sep;14(9):917-27. Epub 2006 Apr 5.

PMID:
16596419
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk